SAN JOSE, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today reported unaudited financial results for the quarter ended March 31, 2024.
Recent Highlights
“We started 2024 with strong revenue growth exceeding 80% and demonstrated disciplined management of operating expenses throughout the first quarter. Now firmly in our San Jose facility, we are in a great position to continue leveraging overhead expenses to improve gross margins throughout the year,” said Reza Zadno, Chief Executive Officer. “With an expanded and more tenured commercial team and growing demand for Aquablation therapy, we are confident in hitting our long-term growth targets.”
First Quarter 2024 Financial Results
Total revenue for the first quarter of 2024 was $44.5 million, an increase of 83% compared to the prior year period. U.S. revenue was $40.2 million dollars, representing growth of 85% compared to the prior year period. The increase was primarily driven by system sales to new hospital customers and increased handpiece revenue. U.S. handpiece and consumable revenue for the first quarter of 2023 was $23.6 million, an increase of 101% compared to the prior year period. First quarter of 2024 monthly utilization per account of 6.8 increased approximately 8% compared to the prior year period. U.S. system revenue for the first quarter of 2024 was $14.2 million, an increase of 62% compared to the prior year period. As of March 31, 2024, the install base of AquaBeam Robotic Systems in the U.S. was 354 systems. International revenue was $4.3 million for the quarter, an increase of 65% compared to the prior year period.
Gross margin for the first quarter 2024 was 56% compared to 51% in the prior year period and 49% in the fourth quarter of 2023. Gross margin expansion in the first quarter was due to strong operational execution and improved overhead absorption, along with revenue overachievement.
Operating expenses in the first quarter of 2024 were $52.7 million, compared with $40.9 million in the prior year period. The increase was driven by increased sales and marketing expenses primarily to expand the commercial organization and variable compensation expense, increased research and development expenses and general and administrative expenses.
Net loss was $26.0 million for the first quarter of 2024, compared to a loss of $28.5 million in the prior year period. Adjusted EBITDA was a loss of $20.4 million for the first quarter of 2024, compared to a loss of $23.9 million in the prior year period.
Cash and short-term investments as of March 31, 2024, totaled $225.6 million, while long-term borrowings totaled $52.0 million.
Full Year 2024 Financial Guidance
Adjusted EBITDA is a financial measure that is not prepared in accordance with generally accepted accounting principles in the United States (GAAP). For more information about the Company’s use of non-GAAP financial measures, please see the section below titled “Use of Non-GAAP Financial Measures (Unaudited).”
Webcast and Conference Call Information
PROCEPT BioRobotics will host a conference call to discuss the first quarter 2024 financial results on Thursday, May 1, 2024, at 8:00 a.m. Eastern Time.
Investors interested in listening to the conference call may do so by following one of the below links:
About PROCEPT BioRobotics Corporation
PROCEPT BioRobotics is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. PROCEPT BioRobotics develops, manufactures and sells the AquaBeam Robotic System, an advanced, image-guided, surgical robotic system for use in minimally invasive urologic surgery with an initial focus on treating benign prostatic hyperplasia, or BPH. BPH is the most common prostate disease and impacts approximately 40 million men in the United States. PROCEPT BioRobotics designed Aquablation therapy to deliver effective, safe and durable outcomes for males suffering from lower urinary tract symptoms, or LUTS, due to BPH that are independent of prostate size and shape or surgeon experience. The Company has developed a significant and growing body of clinical evidence, which includes nine clinical studies and over 150 peer-reviewed publications, supporting the benefits and clinical advantages of Aquablation therapy.
Use of Non-GAAP Financial Measures (Unaudited)
This press release references Adjusted EBITDA, a financial measure that is not prepared in accordance with generally accepted accounting principles in the United States (GAAP). The Company defines Adjusted EBITDA as earnings before interest expense, taxes, depreciation and amortization and stock-based compensation. Non-GAAP financial measures are not a substitute for or superior to measures of financial performance prepared in accordance with GAAP and should not be considered as an alternative to any other performance measures derived in accordance with GAAP.
The Company believes that presenting Adjusted EBITDA provides useful supplemental information to investors about the Company in understanding and evaluating its operating results, enhancing the overall understanding of its past performance and future prospects, and allowing for greater transparency with respect to key financial metrics used by its management in financial and operational decision making. However, there are a number of limitations related to the use of non-GAAP measures and their nearest GAAP equivalents. For example, other companies may calculate non-GAAP measures differently, or may use other measures to calculate their financial performance, and therefore any non-GAAP measures the Company uses may not be directly comparable to similarly titled measures of other companies.
Forward Looking Statements
This release contains forward‐looking statements within the meaning of federal securities laws, including with respect to the Company’s projected financial performance for full year 2024, statements regarding the potential utilities, values, benefits and advantages of Aquablation® therapy performed using PROCEPT BioRobotics’ products, including AquaBeam® Robotic System, which involve risks and uncertainties that could cause the actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements. Forward-looking statements are only predictions based on our current expectations, estimates, and assumptions, valid only as of the date they are made, and subject to risks and uncertainties, some of which we are not currently aware. Forward-looking statements may include statements regarding financial guidance, market opportunity and penetration, the Company’s possible or assumed future results of operations, including descriptions of the Company’s revenues, gross margin, profitability, operating expenses, installed base growth, commercial momentum, reimbursement coverage, overall business strategy, or information regarding the impact of other global events on the Company and its operations. Forward‐looking statements should not be read as a guarantee of future performance or results and may not necessarily be accurate indications of the times at, or by, which such performance or results will be achieved. These forward‐looking statements are based on the Company’s current expectations and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward‐looking statements as a result of these risks and uncertainties. These risks and uncertainties are described more fully in the section titled “Risk Factors” in the Company’s filings with the Securities and Exchange Commission (the “SEC”), including the Company’s annual report on Form 10-K filed with the SEC on February 28, 2024. PROCEPT BioRobotics does not undertake any obligation to update forward‐looking statements and expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward‐looking statements contained herein. These forward-looking statements should not be relied upon as representing PROCEPT BioRobotics’ views as of any date subsequent to the date of this press release.
Important Safety Information
All surgical treatments have inherent and associated side effects. For a list of potential side effects visit https://aquablation.com/safety-information/
Investor Contact:
Matt Bacso
VP, Investor Relations and Business Operations
This email address is being protected from spambots. You need JavaScript enabled to view it.
| PROCEPT BioRobotics Corporation CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited, in thousands, except per share data) | ||||||||
| Three Months Ended March 31, | ||||||||
| 2024 | 2023 | |||||||
| Revenue | $ | 44,539 | $ | 24,404 | ||||
| Cost of sales | 19,505 | 11,913 | ||||||
| Gross profit | 25,034 | 12,491 | ||||||
| Operating expenses: | ||||||||
| Research and development | 13,084 | 10,737 | ||||||
| Selling, general and administrative | 39,599 | 30,131 | ||||||
| Total operating expenses | 52,683 | 40,868 | ||||||
| Loss from operations | (27,649 | ) | (28,377 | ) | ||||
| Interest expense | (1,045 | ) | (886 | ) | ||||
| Interest and other income, net | 2,737 | 779 | ||||||
| Net loss | $ | (25,957 | ) | $ | (28,484 | ) | ||
| Net loss per share, basic and diluted | $ | (0.51 | ) | $ | (0.63 | ) | ||
| Weighted-average common shares used to | ||||||||
| Compute net loss per share attributable to | ||||||||
| Common shareholders, basic and diluted | 51,011 | 45,066 | ||||||
| PROCEPT BioRobotics Corporation RECONCILIATION OF GAAP NET LOSS TO ADJUSTED EBITDA (Unaudited, in thousands) | ||||||||
| Three Months Ended March 31, | ||||||||
| 2024 | 2023 | |||||||
| Net loss | $ | (25,957 | ) | $ | (28,484 | ) | ||
| Depreciation and amortization expense | 1,184 | 793 | ||||||
| Stock-based compensation expense | $ | 6,256 | 3,724 | |||||
| Interest (income) and interest expense, net | (1,838 | ) | 49 | |||||
| Adjusted EBITDA | $ | (20,355 | ) | $ | (23,918 | ) | ||
| PROCEPT BioRobotics Corporation RECONCILIATION OF GAAP NET LOSS TO ADJUSTED 2024 EBITDA Guidance (Unaudited, in thousands) | |||||
| 2024 | |||||
| Net loss | $ | (100,000 | ) | ||
| Depreciation and amortization expense | 5,645 | ||||
| Stock-based compensation expense | 31,500 | ||||
| Interest (income) and interest expense, net | (7,145 | ) | |||
| Adjusted EBITDA | $ | (70,000 | ) | ||
| PROCEPT BioRobotics Corporation CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited, in thousands) | ||||||||
| March 31, 2024 | December 31, 2023 | |||||||
| Assets | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 225,576 | $ | 257,222 | ||||
| Accounts receivable, net | 56,081 | 48,376 | ||||||
| Inventory | 41,622 | 39,756 | ||||||
| Prepaid expenses and other current assets | 5,907 | 5,213 | ||||||
| Total current assets | 329,186 | 350,567 | ||||||
| Restricted cash, non-current | 3,038 | 3,038 | ||||||
| Property and equipment, net | 28,488 | 28,748 | ||||||
| Operating lease right-of-use assets, net | 19,892 | 20,241 | ||||||
| Intangible assets, net | 1,136 | 1,204 | ||||||
| Other assets | 1,160 | 919 | ||||||
| Total assets | $ | 382,900 | $ | 404,717 | ||||
| Liabilities and Stockholders' Equity | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 10,084 | $ | 13,499 | ||||
| Accrued compensation | 11,469 | 16,885 | ||||||
| Deferred revenue | 5,860 | 5,656 | ||||||
| Operating leases, current | 1,701 | 1,683 | ||||||
| Loan facility derivative liability, current | 1,914 | 1,886 | ||||||
| Other current liabilities | 7,622 | 6,318 | ||||||
| Total current liabilities | 38,650 | 45,927 | ||||||
| Long-term debt | 51,371 | 51,339 | ||||||
| Operating leases, non-current | 28,315 | 26,182 | ||||||
| Other liabilities | 517 | 517 | ||||||
| Total liabilities | 118,853 | 123,965 | ||||||
| Stockholders’ equity: | ||||||||
| Additional paid-in capital | 744,463 | 735,240 | ||||||
| Accumulated other comprehensive gain | 113 | 84 | ||||||
| Accumulated deficit | (480,529 | ) | (454,572 | ) | ||||
| Total stockholders’ equity | 264,047 | 280,752 | ||||||
| Total liabilities and stockholders’ equity | $ | 382,900 | $ | 404,717 | ||||
| PROCEPT BioRobotics Corporation REVENUE BY TYPE AND GEOGRAPHY (Unaudited, in thousands) | ||||||
| Three Months Ended March 31, | ||||||
| 2024 | 2023 | |||||
| U.S. | ||||||
| System sales and rentals | $ | 14,236 | $ | 8,770 | ||
| Handpieces and other consumables | 23,618 | 11,770 | ||||
| Service | 2,347 | 1,235 | ||||
| Total U.S. revenue | 40,201 | 21,775 | ||||
| Outside of U.S. | ||||||
| System sales and rentals | 1,740 | 1,469 | ||||
| Handpieces and other consumables | 2,343 | 906 | ||||
| Service | 255 | 254 | ||||
| Total outside of U.S. revenue | 4,338 | 2,629 | ||||
| Total revenue | $ | 44,539 | $ | 24,404 | ||
| Last Trade: | US$93.60 |
| Daily Change: | -0.85 -0.90 |
| Daily Volume: | 343,223 |
| Market Cap: | US$4.860B |
October 28, 2024 October 28, 2024 October 07, 2024 August 28, 2024 August 21, 2024 | |
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MORE
